Faron Pharmaceuticals Oy (HEL:FARON)

Finland flag Finland · Delayed Price · Currency is EUR
2.550
+0.030 (1.19%)
At close: Jun 6, 2025
99.53%
Market Cap 331.91M
Revenue (ttm) n/a
Net Income (ttm) -25.92M
Shares Out n/a
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 386,581
Average Volume 529,938
Open 2.505
Previous Close 2.520
Day's Range 2.435 - 2.555
52-Week Range 1.054 - 3.345
Beta 1.18
RSI 44.74
Earnings Date Aug 27, 2025

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 25
Stock Exchange Nasdaq Helsinki
Ticker Symbol FARON
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.